查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1617792

体外诊断市场：按组件、技术、检体、应用和最终用户划分 - 2025-2030 年全球预测

In-Vitro Diagnostics Market by Component (Data Management Software & Services, Instruments, Reagents & Kits), Technology (Clinical Chemistry, Coagulation & Hemostasis, Hematology), Specimen, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年体外诊断市值为1,090.5亿美元，预计到2024年将达到1,150.4亿美元，复合年增长率为6.11%，到2030年将达到1,652.7亿美元。

体外诊断 (IVD) 包括用于在体外受控环境中检体人体样本（例如血液、组织和其他体液）的医疗设备和测试方法。对体外诊断药物的需求源于它们在诊断疾病、监测健康状况、预测疾病进展和确定治疗策略方面发挥的重要作用。体外诊断用于多种领域，包括感染疾病、肿瘤学、心臟病学、内分泌学和基因检测。最终用户主要包括医院、诊断实验室、学术机构和就地检验中心。市场成长的主要驱动力包括技术进步、慢性病和感染疾病患者病率的增加、对个人化医疗的需求不断增加以及对疾病早期诊断的认识不断提高。人工智慧和自动化在诊断中的整合有望提高准确性和效率，并带来重大机会。此外，尤其是由于新冠肺炎 (COVID-19) 大流行，家庭检测的转变为开髮用户友好型快速检测提供了机会。然而，严格的监管要求、与先进诊断相关的高成本以及报销限制正在阻碍市场成长。其他挑战包括来自替代疾病检测方法的竞争以及将新技术融入现有系统的复杂性。对于公司而言，分子诊断、次世代定序和携带式诊断设备等领域的创新提供了一个有希望的成长途径。投资研发以提高测试特异性和灵敏度以及开发具有成本效益的技术对于市场扩张至关重要。此外，主要相关人员之间的合作和伙伴关係可以简化创新和市场渗透。市场是动态的，其特点是技术不断发展和竞争格局不断变化，需要不断适应和策略变革。公司必须积极应对监管挑战，并利用数位医疗解决方案等新兴趋势来维持和扩大其市场份额。

主要市场统计
基准年[2023] 1090.5亿美元
预测年份 [2024] 1150.4亿美元
预测年份 [2030] 1652.7亿美元
复合年增长率（%） 6.11%

市场动态：快速发展的体外诊断市场的关键市场洞察

供需的动态交互作用正在改变体外诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性病及感染疾病率增加
    • 随着伴同性诊断的普及，对个人化治疗的关注日益增加
    • 政府积极进行健康意识宣传活动和体检
  • 市场限制因素
    • 缺乏针对特定诊断测试的全面报销政策
  • 市场机会
    • 随着医疗保健基础设施的发展，POC 测试范围不断扩大
    • 数位健康平台和诊断集成
  • 市场挑战
    • 体外诊断的严格法规和核准流程

波特五力：驾驭体外诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解体外诊断市场的外部影响

外部宏观环境因素在塑造体外诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解体外诊断市场的竞争状况

体外诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵体外诊断市场供应商绩效评估

FPNV定位矩阵是评估体外诊断市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘 IVD 市场的成功之路

体外诊断市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病及感染疾病率增加
      • 日益关注个人化治疗并增加伴同性诊断的引入
      • 政府对健康意识宣传活动和检测采取的有利方法
    • 抑制因素
      • 缺乏针对特定诊断测试的全面报销政策
    • 机会
      • 扩大医疗基础设施和扩大就地检验
      • 诊断和数位健康平台的集成
    • 任务
      • 与体外诊断相关的严格法规和核准流程
  • 市场区隔分析
    • 组成部分：仪器和试剂在体外诊断中的重要作用
    • 应用：体外诊断在癌症治疗的创新应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章体外诊断市场：依组成部分

  • 资料管理软体和服务
  • 装置
  • 试剂和套件

第七章体外诊断市场：依技术分类

  • 临床化学
    • 基础代谢组
    • 电解质板
    • 血脂谱
    • 肝臟组
    • 肾臟概况
    • 特殊化学测试
    • 甲状腺功能检查
  • 凝血和止血
  • 血液学
  • 免疫化学
    • 酵素免疫分析法
      • 化学冷光免疫检测
      • 免疫检测
      • 萤光免疫分析法
    • 酵素连结免疫斑点测定
    • 免疫检测
    • 快速测试
    • 蛋白质印迹法
  • 微生物学
  • 分子诊断
    • DNA定序与次世代定序
    • 交配
    • 恒温核酸增幅技术
    • 微阵列
    • 聚合酵素链锁反应
  • 尿液检查

第八章 体外诊断标本市场

  • 血液、血清、血浆
  • 唾液
  • 尿

第九章体外诊断市场：依应用分类

  • 自体免疫疾病
  • 心臟病学
  • 糖尿病
  • 药物测试
  • 爱滋病毒/爱滋病
  • 感染疾病
  • 肾臟病学
  • 肿瘤学

第 10 章 体外诊断市场：依最终使用者分类

  • 医院和护理提供者
  • 研究所
  • 患者自查

第十一章 北美和南美体外诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区体外诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲体外诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Biocare Medical 的先进抗原修復室 (ARC) 彻底改变了免疫组织化学
    • GenWorks Health 推出登革热和疟疾 IVD 检测
    • Oxford Nanopore 与生物梅里埃签署策略合作协议，开发创新的感染疾病诊断
  • 战略分析和建议

公司名单

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • Adaptive Biotechnologies Corp
  • Agilent Technologies Inc.
  • Arkray Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Biomerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • EKF GmbH
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Hologic, Inc.
  • Illumina, Inc.
  • Menarini Diagnostics
  • Mindray Medical International Limited
  • Myriad Genetics, Inc.
  • Ortho-Clinical Diagnostics, Inc.
  • Qiagen GmbH
  • Randox Laboratories
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-434CCDA04D33

The In-Vitro Diagnostics Market was valued at USD 109.05 billion in 2023, expected to reach USD 115.04 billion in 2024, and is projected to grow at a CAGR of 6.11%, to USD 165.27 billion by 2030.

In-Vitro Diagnostics (IVD) encompasses medical devices and assays used to test specimens derived from the human body, such as blood, tissues, and other body fluids, outside the body in a controlled environment. The necessity for IVD arises from its critical role in diagnosing diseases, monitoring health, predicting disease progression, and guiding treatment decisions. Applications of IVD range across various domains, including infectious diseases, oncology, cardiology, endocrinology, and genetic testing. End-users primarily include hospitals, diagnostic laboratories, academic institutions, and point-of-care testing centers. Key market growth drivers include advancements in technology, an increasing prevalence of chronic and infectious diseases, the growing demand for personalized medicine, and heightened awareness of early disease diagnosis. The integration of artificial intelligence and automation in diagnostics presents a significant opportunity, promising enhanced accuracy and efficiency. Furthermore, the shift towards home-based testing especially poised by the COVID-19 pandemic, corroborates opportunities in developing user-friendly and rapid tests. However, market growth is hindered by stringent regulatory requirements, high costs associated with advanced diagnostics, and reimbursement constraints. Challenges also include the competition from alternative disease testing methodologies and the complexity of integrating novel technologies into existing systems. For businesses, innovation in areas such as molecular diagnostics, next-generation sequencing, and portable diagnostic devices offers promising growth avenues. Investing in research to enhance test specificity and sensitivity, and developing cost-effective technologies, are crucial for market expansion. Moreover, collaborations and partnerships among key stakeholders can streamline innovation and market penetration. The market is dynamic, characterized by continuous technological evolution and competitive landscape, necessitating continuous adaptation and strategy modulation. Businesses must remain proactive in addressing regulatory challenges and leverage emerging trends, such as digital healthcare solutions, to sustain and grow their market presence.

KEY MARKET STATISTICS
Base Year [2023] USD 109.05 billion
Estimated Year [2024] USD 115.04 billion
Forecast Year [2030] USD 165.27 billion
CAGR (%) 6.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In-Vitro Diagnostics Market

The In-Vitro Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic and infectious diseases
    • Growing focus on personalized treatment coupled with increased adoption of companion diagnostics
    • Favourable government initiative for health awareness campaigns and screenings
  • Market Restraints
    • Lack of comprehensive reimbursement policies for certain diagnostic tests
  • Market Opportunities
    • Expansion of point-of-care testing coupled with growing healthcare infrastructure
    • Integration of diagnostics with digital health platforms
  • Market Challenges
    • Stringent regulations and approval processes associated with in vitro diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the In-Vitro Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In-Vitro Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In-Vitro Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In-Vitro Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In-Vitro Diagnostics Market

A detailed market share analysis in the In-Vitro Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In-Vitro Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In-Vitro Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In-Vitro Diagnostics Market

A strategic analysis of the In-Vitro Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Abbott Laboratories, Adaptive Biotechnologies Corp, Agilent Technologies Inc., Arkray Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biomerieux SA, Danaher Corporation, DiaSorin S.p.A., EKF GmbH, F. Hoffmann-La Roche Ltd., Grifols SA, Hologic, Inc., Illumina, Inc., Menarini Diagnostics, Mindray Medical International Limited, Myriad Genetics, Inc., Ortho-Clinical Diagnostics, Inc., Qiagen GmbH, Randox Laboratories, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Data Management Software & Services, Instruments, and Reagents & Kits.
  • Based on Technology, market is studied across Clinical Chemistry, Coagulation & Hemostasis, Hematology, Immunochemistry, Microbiology, Molecular Diagnostics, and Urinalysis. The Clinical Chemistry is further studied across Basic Metabolic Panel, Electrolyte Panel, Lipid Profile, Liver Panel, Renal Profile, Specialty Chemical Tests, and Thyroid Function Panel. The Immunochemistry is further studied across Enzyme-Linked Immunosorbent Assay, Enzyme-Linked Immunospot Assays, Radioimmunoassay, Rapid Test, and Western Blotting. The Enzyme-Linked Immunosorbent Assay is further studied across Chemiluminescence Immunoassays, Colorimetric Immunoassays, and Fluorescence Immunoassays. The Molecular Diagnostics is further studied across DNA Sequencing & Next-Generation Sequencing, Hybridization, Isothermal Nucleic Acid Amplification Technology, Microarray, and Polymerase Chain Reaction.
  • Based on Specimen, market is studied across Blood, Serum & Plasma, Saliva, and Urine.
  • Based on Application, market is studied across Autoimmune Diseases, Cardiology, Diabetes, Drug Testing, HIV/Aids, Infectious Diseases, Nephrology, and Oncology.
  • Based on End User, market is studied across Hospitals & Care Providers, Laboratories, and Patient Self-Testing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic and infectious diseases
      • 5.1.1.2. Growing focus on personalized treatment coupled with increased adoption of companion diagnostics
      • 5.1.1.3. Favourable government initiative for health awareness campaigns and screenings
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of comprehensive reimbursement policies for certain diagnostic tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of point-of-care testing coupled with growing healthcare infrastructure
      • 5.1.3.2. Integration of diagnostics with digital health platforms
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and approval processes associated with in vitro diagnostics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: The integral role of instruments, and reagents in in-vitro diagnostics
    • 5.2.2. Application: Revolutionizing application of in-vitro diagnostic in cancer care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. In-Vitro Diagnostics Market, by Component

  • 6.1. Introduction
  • 6.2. Data Management Software & Services
  • 6.3. Instruments
  • 6.4. Reagents & Kits

7. In-Vitro Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Clinical Chemistry
    • 7.2.1. Basic Metabolic Panel
    • 7.2.2. Electrolyte Panel
    • 7.2.3. Lipid Profile
    • 7.2.4. Liver Panel
    • 7.2.5. Renal Profile
    • 7.2.6. Specialty Chemical Tests
    • 7.2.7. Thyroid Function Panel
  • 7.3. Coagulation & Hemostasis
  • 7.4. Hematology
  • 7.5. Immunochemistry
    • 7.5.1. Enzyme-Linked Immunosorbent Assay
      • 7.5.1.1. Chemiluminescence Immunoassays
      • 7.5.1.2. Colorimetric Immunoassays
      • 7.5.1.3. Fluorescence Immunoassays
    • 7.5.2. Enzyme-Linked Immunospot Assays
    • 7.5.3. Radioimmunoassay
    • 7.5.4. Rapid Test
    • 7.5.5. Western Blotting
  • 7.6. Microbiology
  • 7.7. Molecular Diagnostics
    • 7.7.1. DNA Sequencing & Next-Generation Sequencing
    • 7.7.2. Hybridization
    • 7.7.3. Isothermal Nucleic Acid Amplification Technology
    • 7.7.4. Microarray
    • 7.7.5. Polymerase Chain Reaction
  • 7.8. Urinalysis

8. In-Vitro Diagnostics Market, by Specimen

  • 8.1. Introduction
  • 8.2. Blood, Serum & Plasma
  • 8.3. Saliva
  • 8.4. Urine

9. In-Vitro Diagnostics Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cardiology
  • 9.4. Diabetes
  • 9.5. Drug Testing
  • 9.6. HIV/Aids
  • 9.7. Infectious Diseases
  • 9.8. Nephrology
  • 9.9. Oncology

10. In-Vitro Diagnostics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals & Care Providers
  • 10.3. Laboratories
  • 10.4. Patient Self-Testing

11. Americas In-Vitro Diagnostics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific In-Vitro Diagnostics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa In-Vitro Diagnostics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Biocare Medical's Advanced Antigen Retrieval Chamber (ARC), Revolutionizing Immunohistochemistry
    • 14.3.2. GenWorks Health launches IVD tests for dengue & malaria
    • 14.3.3. Oxford Nanopore and bioMerieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 10x Genomics, Inc.
  • 2. Abbott Laboratories
  • 3. Adaptive Biotechnologies Corp
  • 4. Agilent Technologies Inc.
  • 5. Arkray Inc.
  • 6. Becton, Dickinson and Company
  • 7. Bio-Rad Laboratories Inc.
  • 8. Biomerieux SA
  • 9. Danaher Corporation
  • 10. DiaSorin S.p.A.
  • 11. EKF GmbH
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Grifols SA
  • 14. Hologic, Inc.
  • 15. Illumina, Inc.
  • 16. Menarini Diagnostics
  • 17. Mindray Medical International Limited
  • 18. Myriad Genetics, Inc.
  • 19. Ortho-Clinical Diagnostics, Inc.
  • 20. Qiagen GmbH
  • 21. Randox Laboratories
  • 22. Siemens AG
  • 23. Sysmex Corporation
  • 24. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IN-VITRO DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BASIC METABOLIC PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIPID PROFILE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RENAL PROFILE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIALTY CHEMICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DRUG TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEPHROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT SELF-TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 244. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 245. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 247. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 254. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 255. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 256. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 257. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 263. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 265. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 266. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 267. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 272. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 273. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 274. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 275. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 276. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 277. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 281. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 283. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 284. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 285. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 286. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 287. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 289. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 290. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 291. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 292. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 293. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 294. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 295. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 296. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 299. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 300. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 301. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 302. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 303. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 304. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 305. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 306. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 307. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 308. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 310. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 311. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 312. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 313. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 314. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 315. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 316. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 317. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 318. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 319. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 320. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 321. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 322. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 323. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 325. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 326. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 327. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 328. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 329. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 330. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 331. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 332. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATIO